A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-05

Study Completion Date

2024-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts:

* Cohort A: CRC
* Cohort B: Gastric and GEJ cancer
* Cohort C: TNBC
* Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

NCT00705874

Cancer

COMPLETED PHASE1

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

NCT02079740

Metastatic Malignant Solid Neoplasm Refractory Malignant Solid Neoplasm Unresectable Malignant Solid Neoplasm

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

NCT03314935

Biliary Tract Cancer (BTC) Colorectal Cancer (CRC) Endometrial Cancer +3 more

COMPLETED PHASE1/PHASE2

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

NCT02887248

Urothelial Carcinoma Bladder Cancer Transitional Cell Carcinoma

TERMINATED PHASE2

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

NCT03498521

Cancer of Unknown Primary Site

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After completing all screening procedures, including the submission of a tissue sample, patients that meet eligibility requirements will be assigned to receive navicixizumab alone or in combination with another anticancer agent. Treatment is assigned based on the patients type of tumor and the cohort that is open at the time of enrollment. Patients will receive treatment in 4 week cycles, attend study visits and have their heart monitored through echocardiograms and daily blood pressure measurements. Patients will also have their tumors monitored regularly through CT scans. Patients receiving benefit may continue on study drug until their tumor progresses, they experience intolerable side effects, their physician decides it is in their best interest to discontinue therapy or they choose to withdrawal from the study. After discontinuing study treatments, all patients will receive regular follow up calls or visits to assess their status and other anticancer treatments they may start.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Triple Negative Breast Cancer Gastric Cancer Ovarian Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Combination navicixizumab + paclitaxel

Gastric/GEJ and TNBC cancer patients will be assigned to this treatment arm.

Group Type EXPERIMENTAL

navicixizumab+paclitaxel

Intervention Type BIOLOGICAL

navicixizumab 3 mg/kg Q2W; paclitaxel 80 mg/m2 weekly

Combination navicixizumab + irinotecan

CRC patients will be assigned to this treatment arm.

Group Type EXPERIMENTAL

navicixizumab+irinotecan

Intervention Type BIOLOGICAL

navicixizumab 3 mg/kg Q2W; irinotecan 180 mg/m2 Q2W

Navicixizumab monotherapy

CRC,TNBC and ovarian cancer patients will be assigned to this treatment arm.

Group Type EXPERIMENTAL

navicixizumab monotherapy

Intervention Type BIOLOGICAL

navicixizumab 3 mg/kg Q2W

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

navicixizumab+paclitaxel

navicixizumab 3 mg/kg Q2W; paclitaxel 80 mg/m2 weekly

Intervention Type BIOLOGICAL

navicixizumab+irinotecan

navicixizumab 3 mg/kg Q2W; irinotecan 180 mg/m2 Q2W

Intervention Type BIOLOGICAL

navicixizumab monotherapy

navicixizumab 3 mg/kg Q2W

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient provides informed consent.
2. Patient is ≥18 years old.
3. Patient has one of the following locally advanced or metastatic, unresectable solid malignancies that is incurable:

* CRC
* Gastric or GEJ cancer
* TNBC
* Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer
4. Patient has provided an FFPE archive or newly obtained core or excisional biopsy of a tumor lesion.
5. Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
6. Patient has measurable disease, as defined by RECIST v1.1.
7. Patient has adequate organ function.
8. Female patients of childbearing potential must have a negative pregnancy test.
9. Female patients of childbearing potential must agree to follow instructions for highly effective method(s) of contraception while receiving study treatment and for 6 months after the last dose of study drug.
10. Male patients with female sexual partners of childbearing potential must agree to use an acceptable form of contraception while receiving study treatment and for 6 months after the last dose of any study drug.
11. Patient is willing and able to comply with scheduled visits and procedures.
12. Patient must have discontinued other anticancer interventions before Cycle 1 Day 1 per study protocol.

Cohort A1 and Cohort A2 - CRC only:
13. Patient has definitive pathologically confirmed adenocarcinoma of the colon or rectum.
14. Patient must have received at least 2 and no more than 3 prior lines of standard therapy for metastatic disease.

Cohort B1 - Gastric/GEJ cancer only:
15. Patient has definitive pathologically confirmed metastatic gastric or GEJ adenocarcinoma that is not amenable to surgery.
16. Patient must have received only 1 prior line of standard therapy for metastatic disease.

Cohort C1 and Cohort C2 - TNBC only:
17. Patient has definitive pathologically confirmed metastatic or locally advanced TNBC that is not amenable to surgery or radiotherapy with curative intent.
18. Patient must have received at least 2 prior and no more than 4 prior lines of standard therapy for metastatic disease.

Cohort D1 - Ovarian cancer only:
19. Patient has definitive pathologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer.
20. Patient must be considered platinum-resistant/refractory.
21. Patient must have received at least 2 and no more than 5 prior lines of standard therapy.

Exclusion Criteria

1. Patient has cardiac conditions as listed in the protocol.
2. Patient has blood pressure (BP) \>140/90 mmHg.
3. Patient is pregnant or lactating.
4. Patient has known untreated, active or uncontrolled brain metastases.
5. Patient with leptomeningeal disease.
6. Patient has a known additional malignancy that was progressing or required active treatment within 2 years prior to the first dose of study medication.
7. Patient has a history of bowel obstruction, including sub-occlusive disease, related to the underlying disease or history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess.
8. Patient has an active infection requiring IV systemic therapy.
9. Patient has known hypersensitivity to any components of any study drug or any of its excipients that, in the opinion of the investigator, suggests a high risk for a severe hypersensitivity reaction while on treatment.
10. Patient has a known clinically significant bleeding disorder.
11. Patient is currently using oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes for which the dose has not been stable for \>14 days prior to C1D1.
12. Patient had hemoptysis \>2.5 mL within 8 weeks prior to C1D1 or serious bleeding from another site within this time frame.
13. Patient had a major surgical procedure, or significant traumatic injury within 28 days prior to C1D1.
14. Patient has an uncontrolled seizure disorder or active neurologic disease.
15. Patient has a cardiac aneurysm.
16. Patient has a known psychiatric disorder, substance abuse disorder, or geographical travel limitations that in the opinion of the investigator would interfere with patient's ability to cooperate with the requirements of the study.
17. Patient has a history or current evidence of any condition, therapy, or laboratory abnormality that may confound the results of the study, interfere with the patient's participation for the full duration of the study, or indicates a condition for which study participation is not in the best interest of the patient, in the opinion of the investigator.

Cohort A1 and Cohort A2 - CRC only:
18. Patient has known microsatellite instability-high status.

Cohort A2 - CRC (navicixizumab + irinotecan) only:
19. Patient is on dialysis.
20. Patient has received hepatic intra-arterial chemotherapy.

Cohort B1 - Gastric/GEJ cancer only:
21. Patient has experienced weight loss \>10% over 2 months prior to first dose of study treatment.
22. Patient has definitive pathologically confirmed HER2 positive metastatic gastric or GEJ adenocarcinoma.
23. Patient has pre-existing Grade ≥2 peripheral neuropathy, according to CTCAE v5.0.

Cohort C2 - TNBC (navicixizumab + paclitaxel) only
24. Patient has pre-existing Grade ≥2 peripheral neuropathy, according to CTCAE v5.0.

Cohort D1 - Ovarian cancer only:
25. Patient has non-epithelial ovarian carcinoma.
26. Patient has ovarian tumors with low malignant potential (ie, borderline tumors).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No